Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder-Reference-Cited by-同舟云学术

Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder

Published:2016-05 Issue: Volume:7 Page:53-57
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Yoshii Fumihito,Moriya Yusuke,Ohnuki Tomohide,Ryo Masafuchi,Takahashi Wakoh

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference5 articles.

1. Fingolomod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: result of a phase 2 observational extension;Kira;BMC Neurol.,2014

2. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis;Saida;Mult. Scler.,2012

3. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder;Min;Mult. Scler.,2012

4. A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment;Izaki;Clin. Neurol.,2013

5. Longitudinally extensive spinal cord lesion after initiation, and multiple extensive brain lesions after cessation of fingolimod treatment in a patient with recurrent myelitis and anti-aquaporin 4 antibodies;Tanaka;Clin. Exp. Neuroimmunol.,2013

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mistakes in the diagnosis of neuromyelitis optic spectrum diseases lead to wrong therapy and deterioration of patients’ condition;S.S. Korsakov Journal of Neurology and Psychiatry;2024

2. Autoantibody-mediated central nervous system channelopathies;Handbook of Clinical Neurology;2024

3. Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder;Frontiers in Immunology;2023-04-14

4. Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder;Journal of Managed Care & Specialty Pharmacy;2022-12

5. Microglial heterogeneity in amyotrophic lateral sclerosis;Journal of Neuropathology & Experimental Neurology;2022-11-28